Search research articles
Contact Us
Filters
Showing results (171-180 of 234) with videos related to
Page
of 24
Sort By:
Cancer Biology & Therapy
|
September 18, 2007
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity
Floris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, et al.
Cancer Chemotherapy and Pharmacology
|
July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
Inge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2015
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
Chee Khoon Lee, David Goldstein, Emma Gibbs, et al.
British Journal of Clinical Pharmacology
|
June 30, 2015
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
Anne-Joy M de Graan, Alex Sparreboom, Peter de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors
Otto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Breast Cancer Research and Treatment
|
June 8, 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
Constantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2012
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne, Sara Cresta, Robert G Maki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors
Salvatore Romeo, Maria Debiec-Rychter, Martine Van Glabbeke, et al.
Page
of 24
Search research articles
Search
Showing results (171-180 of 234) with videos related to
Sort By:
Page
of 24
Cancer Biology & Therapy
|
September 18, 2007
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity
Floris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, et al.
Cancer Chemotherapy and Pharmacology
|
July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
Inge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2015
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
Chee Khoon Lee, David Goldstein, Emma Gibbs, et al.
British Journal of Clinical Pharmacology
|
June 30, 2015
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
Anne-Joy M de Graan, Alex Sparreboom, Peter de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors
Otto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Breast Cancer Research and Treatment
|
June 8, 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
Constantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2012
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne, Sara Cresta, Robert G Maki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors
Salvatore Romeo, Maria Debiec-Rychter, Martine Van Glabbeke, et al.
Page
of 24